Prevention of ischemic stroke in clinical practice: A role of internists and general practitioners

Polskie Archiwum Medycyny Wewnetrznej

Volumn 124, Issue 10, 2014, Pages 540-548

  Niewada, Maciej ^a,b   Członkowska, Anna ^a,b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Ischemic stroke; Prevention; Risk factors; Stroke sequelae; Transient ischemic attack

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANTIHYPERTENSIVE THERAPY; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CLINICAL PRACTICE; GENERAL PRACTITIONER; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INTERNIST; LIFESTYLE MODIFICATION; MORTALITY; NEUROIMAGING; PROGNOSIS; REVIEW; RISK ASSESSMENT; STROKE PATIENT; TRANSIENT ISCHEMIC ATTACK; TREATMENT PLANNING; DOCTOR PATIENT RELATION; FEMALE; GENERAL PRACTICE; HEALTH PERSONNEL ATTITUDE; INTERNAL MEDICINE; ISCHEMIC ATTACK, TRANSIENT; MALE; STANDARDS; STROKE;

ATTITUDE OF HEALTH PERSONNEL; FEMALE; GENERAL PRACTICE; GENERAL PRACTITIONERS; HUMANS; INTERNAL MEDICINE; ISCHEMIC ATTACK, TRANSIENT; MALE; PHYSICIAN-PATIENT RELATIONS; PRACTICE PATTERNS, PHYSICIANS'; PROGNOSIS; RISK ASSESSMENT; STROKE;

EID: 84908476214     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.2464     Document Type: Review

References (59)

1. World Health Organisation. Cerebrovascular Disorders (Offset Publications). Geneva: World Health Organization. 1978.
2. Easton JD, Saver JL, Albers GW, et al. A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease: The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Definition and Evaluation of Transient Ischemic Attack Stroke. 2009;40:2276-2293.
3. Sacco RL, Kasner SE, Broderick J P, et al. An updated definition of stroke for the 21 century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:2064-2089.
4. http://www.who.int/healthinfo/global-burden-disease/estimates-regional/en/. Accessed August 31, 2014.
5. National Audit Office. Department of health. Reducing Brain Damage: Faster access to better stroke care. Report by the Comptroller and auditor general. 2005 HC 452 Session 2005-2006. http://www.nao.org.uk/wp-content/uploads/2005/11/0506452.pdf. Accessed August 31, 2014.
6. Ferri C P, Choenborn C, Kaira L, et al. Prevalence of stroke and related burden among older people living in Latin America, India and China. J Neurol Neurosurg Psychiatry. 2011;82:1074-1082.
7. Burn J, Dennis M, Bamford J, et al. Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. Stroke. 1994;25:333-337.
8. Rothwell PM, Warlow C P. Timing of TIAs preceding stroke: time window for prevention is very short. Neurology. 2005;64:817-820.
9. Giles M F, Rothwell PM. Risk of stroke early after transient ischaemic attack: systematic-review and meta-analysis. Lancet Neurol. 2007;6:1063-1072.
10. Merwick A, Albers GW, Amarenco P, et al. Addition of brain and carotid imaging to the ABCD2 score to identify patients at early risk of stroke after transient ischaemic attack: a multicentre observational study. Lancet Neurol. 2010;9:1060-1069.
11. Kiyohara T, Kamouchi M, Kumai Y, et al. ABCD3 and ABCD3-I Scores Are Superior to ABCD2 Score in the Prediction of Short- and Long-Term Risks of Stroke After Transient Ischemic Attack. Stroke. 2014;45:418-425.
12. Rothwell PM, Coull AJ, Giles M F, et al. Oxford Vascular Study. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet. 2004;363:1925-1933.
13. Luengo-Fernandez R, Gray AM, Rothwell PM. Effect of urgent treatment for transient ischaemic attack and minor stroke on disability and hospital costs (EXPRESS study): a prospective population-based sequential comparison. Lancet Neurol. 2009;8:235-243.
14. Rothwell PM, Giles M F, Chandratheva A, et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet. 2007;370:1432-1442.
15. Lavallee PC, Meseguer E, Abboud H, et al. A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects. Lancet Neurol. 2007;6:953-960.
16. O'Donnell MJ, Xavier D, Liu L, et al. INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376:112-123.
17. Kim J, Gall SL, Dewey HM, et al. Baseline smoking status and the longterm risk of death or nonfatal vascular event in people with stroke: a 10-year survival analysis. Stroke. 2012;43:3173-3178.
18. Cahill K, Stevens S, Perera R, et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;5:CD009329.
19. He FJ, Li J, Macgregor GA. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. BMJ. 2013;346:f1325.
20. Hankey GJ. Nutrition and the risk of stroke. Lancet Neurol. 2012;11:66-81.
21. Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;9894:769-779.
22. Stroke Unit Trialists' Collaboration. Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev. 2013;9:CD000197.
23. IST-3 collaborative group, Sandercock P, Wardlaw JM, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012;379:2352-2363.
24. Maier IL, Bauerle M, Kermer P, et al. Risk prediction of very early recurrence, death and progression after acute ischaemic stroke. Eur J Neurol. 2013;20:599-604.
25. Chen ZM, Sandercock P, Pan HC, et al. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke. 2000;31:1240-1249.
26. Sudlow CL, Mason G, Maurice JB, et al. Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev. 2009;4:CD001246.
27. Wang Y, Wang Y, Zhao X, et al, and the CHANCE investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369:11-19.
28. Johnston SC, Easton JD, Farrant M, et al. Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. Int J Stroke. 2013;8:479-483.
29. Cruz-Flores S, Berge E, Whittle IR. Surgical decompression for cerebral oedema in acute ischaemic stroke. Cochrane Database Syst Rev. 2012;1:CD003435.
30. Rerkasem K, Rothwell PM. Carotid endarterectomy for symptomatic carotid stenosis. Cochrane Database Syst Rev. 2011;4:CD001081.
31. Rothwell PM, Eliasziw M, Gutnikov SA, et al. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet. 2004;363:915-924.
32. Bonati LH, Fraedrich G, and the Carotid Stenting Trialists' Collaboration. Age modifies the relative risk of stenting versus endarterectomy for symptomatic carotid stenosis-a pooled analysis of EVA-3S, SPACE, and ICSS. Eur J Vasc Endovasc Surg. 2011;41:153-158.
33. Rerkasem K, Rothwell PM. Carotid endarterectomy for symptomatic carotid stenosis. Cochrane Database Syst Rev. 2011;4:CD001081.
34. Bonati LH, Lyrer P, Ederle J, et al. Percutaneous transluminal balloon angioplasty and stenting for carotid artery stenosis. Cochrane Database Syst Rev. 2012;9:CD000515.
35. Chimowitz MI, Lynn MJ, Derdeyn C P, et al.; for SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011;365:993-1003.
36. Webb AJ, Rothwell PM. Effect of dose and combination of antihypertensives on interindividual blood pressure variability: a systematic review. Stroke. 2011;42:2860-2865.
37. Webb AJ, Fischer U, Rothwell PM. Effects of β-blocker selectivity on blood pressure variability and stroke: a systematic review. Neurology. 2011;77:731-737.
38. De Lima LG, Soares BG, Saconato H, et al. Beta-blockers for preventing stroke recurrence. Cochrane Database Syst Rev. 2013;5:CD007890.
39. Webb A J S, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010;375:906-915.
40. Liu L, Wang Z, Gong L, et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertens Res. 2009;32:1032-1040.
41. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
42. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;30;364:331-337.
43. Postępowanie w udarze mózgu. Wytyczne Grupy Ekspertów Sekcji Chorób Naczyniowych Polskiego Towarzystwa Neurologicznego. Neurologia i Neurochirurgia Polska. 2012;46(supl 1):S1-S114.
44. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33:2719-2747.
45. Connolly SJ, Eikelboom J, Joyner C, et al.; the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-817.
46. Kernan WN, Ovbiagele B, Black HR, et al.; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160-2236.
47. Lamberts M, Gislason GH, Olesen JB, et al. Oral anticoagulation and antiplatelets in atrial fi brillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol. 2013;62:981-989.
48. McGrath ER, Kapral MK, Fang J, et al.; the Investigators of the Registry of the Canadian Stroke Network. Which risk factors are more associated with ischemic stroke than intracerebral hemorrhage in patients with atrial fibrillation? Stroke. 2012;43:2048-2054.
49. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14:1385-1413.
50. Rengifo-Moreno P, Palacios I F, Junpaparp P, et al. Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2013;34:3342-3352.
51. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8:453-463.
52. Baigent C, Blackwell L, Emberson J, et al.; the Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681.
53. Collins R, Armitage J, Parish S, et al. and the Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757-767.
54. Amarenco P, Goldstein LB, Szarek M, et al.; the SPARCL Investigators. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2007;38:3198-3204.
55. Hackam DG, Spence JD. Combining multiple approaches for the secondary prevention of vascular events after stroke: a quantitative modeling study. Stroke. 2007;38:1881-1885.
56. Asberg S, Henriksson KM, Farahmand B, et al. Ischemic stroke and secondary prevention in clinical practice: a cohort study of 14, 529 patients in the Swedish Stroke Register. Stroke. 2010;41:1338-1342.
57. Bushnell CD, Olson DM, Zhao X, et al.; the AVAIL Investigators. Secondary preventive medication persistence and adherence 1 year after stroke. Neurology. 2011;77:1182-1190.
58. Teo K, Lear S, Islam S, et al.; the PURE Investigators. Prevalence of a healthy lifestyle among individuals with cardiovascular disease in high-, middle- and low-income countries: The Prospective Urban Rural Epidemiology (PURE) study. JAMA. 2013;309:1613-1621.
59. Yusuf S, Islam S, Chow CK, et al.; the Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378:1231-1243.